Adavosertib

Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity.^[1] It is being developed by AstraZeneca.^[2]

It is being investigated as a treatment for pancreatic cancer with phase 1 trial.^[3]^[4] University of Michigan researchers are as of 2019 planning a phase 2 study.^[5]

References[edit | edit source]

↑ "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 17 August 2019.
↑ "AZD1775 | AstraZeneca Open Innovation". openinnovation.astrazeneca.com. Retrieved 17 August 2019.
↑ "Early Activity in Pancreatic [[Cancer]] With New Drug". www.medpagetoday.com. 16 August 2019. Retrieved 17 August 2019. {{cite web}}: URL–wikilink conflict (help)
↑
↑ "AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival". FierceBiotech. Retrieved 17 August 2019.

Adavosertib Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 17 August 2019.

[2] "AZD1775 | AstraZeneca Open Innovation". openinnovation.astrazeneca.com. Retrieved 17 August 2019.

[3] "Early Activity in Pancreatic [[Cancer]] With New Drug". www.medpagetoday.com. 16 August 2019. Retrieved 17 August 2019. {{cite web}}: URL–wikilink conflict (help)

[4] ↑

[5] "AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival". FierceBiotech. Retrieved 17 August 2019.

[1]

[2]

[3]

[4]

[5]